NCT07064395Completed
Bright Light Therapy on Sleep Health in Lung Cancer Patients
Bright Light Therapy to Reduce Sleep Disturbance and Biological Aging in Lung Cancer Patients
Source: ClinicalTrials.gov · Last updated 2 Jul 2026
Brief summary (registry, in English)
The goal of this randomized intervention trial is to determine the effect of bright light therapy on sleep disturbance, as well as to investigate the impacts of bright light therapy on biological age measured by clinical biomarkers. The main questions it aims to answer are: * Does bright light therapy improve sleep patterns (i.e., sleep onset latency, sleep disturbance, and sleep efficiency) in lung cancer patients? * Can bright light therapy slow the rate of aging measured by biological age in lung cancer patients? Researchers will compare bright light therapy group to control group to see if bright light works to reduce sleep disturbance and decelerate biological aging. Participants will: * Receive bright light exposure or usual light exposure every day for 4 weeks * Get blood draw at the baseline and at 4 weeks for clinical biomarkers tests * Complete self-reported sleep, fatigue and stress surveys at the baseline and at 4 weeks * Keep a daily sleep log
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 6 (actual)
- First submitted
- 25 Jun 2025
- Start date
- 9 Jun 2025
- Primary completion date
- 31 Mar 2026
- Lead sponsor
- Henry Ford Health System
- Diseases
- Lung cancer
- NCT number
- NCT07064395
What you commit to
- Study type: Interventional
- Participants enrolled: 6
- From 9 Jun 2025 to the primary completion date, 31 Mar 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- on oxygen therapy
- Engage in shift work or travel across \>3 time zones within 2 weeks prior to the study
Other illness
- Have metastatic cancer
- Current diagnosis of seasonal affective disorder or substance abuse
- Are currently being treated for sleep apnea, restless legs syndrome, or narcolepsy
- Have eye conditions (glaucoma or retinal disease), problem triggered by bright light (e.g., migraine), or take photosensitizing medications (e.g., some porphyrin drugs, antipsychotics, antiarrhythmic agents)
- Participants with cognitive impairment (sores of \<3 mini-cog test)
Other
- Pregnant women
- Take prescribed sedative hypnotics or antipsychotics
- Participants with an Insomnia Severity Index \<8
Who the study is looking for
- \>=18 years of age
- Stage Ib to IIIb primary lung cancer diagnosis
- \>=2 months after completion of primary therapy, patient can continue to be on maintenance/immunotherapy
- ECOG performance status is 0 or 1
- Experience problematic sleep (scores of \>=8 on the Insomnia Severity Index)
- Able to understand, speak, and read English
- Sighted and mentally competent to consent
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Henry Ford Health System Coordinator of this site? Confirm its status | Detroit | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.